

BLENREP (belantamab mafodotin-blmf) for injection 100 mg REMS Eye Care Professional Consult Request Form



This patient is being treated with BLENREP (belantamab mafodotin-blmf). BLENREP can cause changes in the corneal epithelium, resulting in changes in vision, including severe vision loss and corneal ulcer, and symptoms, such as blurred vision and dry eyes.

Conduct ophthalmic examinations (visual acuity and slit lamp) at baseline, prior to each dose, and promptly for worsening symptoms.

The information that is requested in this form is vital for the prescriber of BLENREP to make treatment and dose modification decisions.

INSTRUCTIONS

- Please complete this form and provide to the prescriber. This form may be faxed, carried by the patient, or adapted into healthcare technology.

Patient Information			
First Name:	Middle Initial:	Last Name:	
Date of Birth (MM/DD/YYYY):		Phone:	
Prescriber Information			
First Name:	Last Name:		
Phone:	Fax:	Email:	
Eye Care Professional Information			
First Name:	Last Name:	Credentials:	
Phone:	Fax:	Email:	
Information for Eye Care Professional			
The prescriber will determine the recommended dosage modification of BLENREP based on the worst finding(s) in the worst affected eye.			
During the ophthalmic exam, the eye care professional should:			
<ul style="list-style-type: none">• Assess the patient for corneal examination finding(s) and decline of best corrected visual acuity (BCVA).• Determine the most severely affected eye as both eyes may not be affected to the same degree.• Report the grade for the worst eye for examination finding(s) and BCVA to the treating physician by using Table 1 Corneal Adverse Reactions for KVA Scale, which was used in the clinical trial.			
Corneal Examination Findings and Best Corrected Visual Acuity			
<i>Please refer to Table 1 for information on relevant examination findings for BLENREP.</i>			
Date of Assessment: _____			
Section 1: For Baseline Examination Only			
<ul style="list-style-type: none">• What are the current best corrected Snellen visual acuity results?			
OD ___/___ OS ___/___			



Eye Care Professional Consult Request Form

First Name:	Middle Initial:	Last Name:	Date of Birth (MM/DD/YYYY):
-------------	-----------------	------------	-----------------------------

Section 2: For Follow-Up Examinations

- What are the current best corrected Snellen visual acuity results?

OD ___/___ OS ___/___

- Were there findings upon corneal examination and/or visual acuity assessment? Yes No

If **Y**, please check affected eyes:

- OD
- OS
- OU

Corneal Examination Findings and Change in BCVA from Baseline for Right Eye

	Corneal Examination Findings <i>Check One</i>	Changes in BCVA from Baseline (per Snellen Visual Acuity) <i>Check One</i>
Right eye (OD)	<input type="checkbox"/> No change from baseline <input type="checkbox"/> Mild superficial keratopathy <input type="checkbox"/> Moderate superficial keratopathy <input type="checkbox"/> Severe superficial keratopathy <input type="checkbox"/> Corneal epithelial defect	<input type="checkbox"/> No change from baseline <input type="checkbox"/> Decline from baseline of 1 line on Snellen Visual Acuity <input type="checkbox"/> Decline from baseline of 2 or 3 lines on Snellen Visual Acuity and not worse than 20/200 <input type="checkbox"/> Decline from baseline by more than 3 lines on Snellen Visual Acuity and not worse than 20/200 <input type="checkbox"/> Snellen Visual Acuity worse than 20/200
	Additional Corneal Examination Findings:	

Corneal Examination Findings and BCVA Changes from Baseline for Left Eye

	Corneal Examination Findings <i>Check One</i>	Changes in BCVA from Baseline (per Snellen Visual Acuity) <i>Check One</i>
Left eye (OS)	<input type="checkbox"/> No change from baseline <input type="checkbox"/> Mild superficial keratopathy <input type="checkbox"/> Moderate superficial keratopathy <input type="checkbox"/> Severe superficial keratopathy <input type="checkbox"/> Corneal epithelial defect	<input type="checkbox"/> No change from baseline <input type="checkbox"/> Decline from baseline of 1 line on Snellen Visual Acuity <input type="checkbox"/> Decline from baseline of 2 or 3 lines on Snellen Visual Acuity and not worse than 20/200 <input type="checkbox"/> Decline from baseline by more than 3 lines on Snellen Visual Acuity and not worse than 20/200 <input type="checkbox"/> Snellen Visual Acuity worse than 20/200
	Additional Corneal Examination Findings:	

Section 3: What is the current grading from the examination finding(s) and BCVA? (Report the grade for the worst eye by checking the box.)

Table 1. Corneal Adverse Reactions for KVA Scale.^a

Report the grade for the worst eye by checking the box	Grade	Corneal Adverse Reaction
<input type="checkbox"/>	Normal	<i>Corneal examination finding(s)</i> Cornea clear / No change from baseline <i>Change in BCVA^b:</i> No decline from baseline of 1 line on Snellen Visual Acuity
<input type="checkbox"/>	Grade 1	<i>Corneal examination finding(s)</i> Mild superficial keratopathy ^c <i>Change in BCVA^b:</i> Decline from baseline of 1 line on Snellen Visual Acuity
<input type="checkbox"/>	Grade 2	<i>Corneal examination finding(s):</i> Moderate superficial keratopathy ^d <i>Change in BCVA^b:</i> Decline from baseline of 2 or 3 lines on Snellen Visual Acuity and not worse than 20/200
<input type="checkbox"/>	Grade 3	<i>Corneal examination finding(s):</i> Severe superficial keratopathy ^e <i>Change in BCVA^b:</i> Decline from baseline by more than 3 lines on Snellen Visual Acuity and not worse than 20/200
<input type="checkbox"/>	Grade 4	<i>Corneal examination finding(s):</i> Corneal epithelial defect ^f <i>Change in BCVA^b:</i> Snellen Visual Acuity worse than 20/200

^a Adapted and modified from the Prescribing Information.

^b Changes in visual acuity due to treatment-related corneal findings.

^c Mild superficial keratopathy (documented worsening from baseline), with or without symptoms.

^d Moderate superficial keratopathy with or without patchy microcyst-like deposits, sub-epithelial haze (peripheral), or a new peripheral stromal opacity.

^e Severe superficial keratopathy with or without diffuse microcyst-like deposits, sub-epithelial haze (central), or a new central stromal opacity.

^f Corneal epithelial defect such as corneal ulcers.

Trademarks are owned by or licensed to the GSK group of companies.



©2020 GSK or licensor.
BLMLTR200016 September 2020
Produced in USA. 0002-0009-20